8-KLeadership ChangesCorporate ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Dec 11, 2013)

Filed December 11, 2013For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on December 11, 2013, reporting key changes to its Board of Directors and corporate governance. The most significant event is the election of Thomas J. Lynch, Jr., M.D., to the Board of Directors, effective January 1, 2014. Dr. Lynch brings extensive expertise as the director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, and he will serve on the Science and Technology Committee. His appointment increases the Board size to eleven and is expected to enhance the company's scientific and strategic direction. Additionally, the company amended its Bylaws to adjust the retirement age for non-employee directors, the CEO, and retired CEOs. The mandatory retirement age has been raised from 72 to 75, effective December 10, 2013. This change allows for greater retention of experienced directors. These updates signal a proactive approach by BMY's leadership to refine board composition and governance structures, aiming to support long-term strategic objectives.

Key Highlights

  • 1Election of Dr. Thomas J. Lynch, Jr., M.D. to the Board of Directors, effective January 1, 2014, expanding the board to eleven members.
  • 2Dr. Lynch's appointment adds significant oncology and medical expertise, given his roles at Yale Cancer Center and Smilow Cancer Hospital.
  • 3Dr. Lynch will serve on the Science and Technology Committee, indicating a focus on scientific innovation and strategy.
  • 4The company amended its Bylaws to raise the mandatory retirement age for non-employee directors, the CEO, and retired CEOs from 72 to 75.
  • 5The revised retirement policy aims to retain experienced leadership and board members.
  • 6The Board of Directors has determined Dr. Lynch to be independent under NYSE and company standards.
  • 7Dr. Lynch will receive standard compensation for non-employee directors, including retainer fees and deferred share units.

Frequently Asked Questions

Dr. Thomas J. Lynch, Jr., is a distinguished medical professional, serving as the director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven. His appointment to the Bristol-Myers Squibb Board of Directors is intended to bring valuable expertise in oncology and scientific research to the company's strategic decision-making.

The company amended its Bylaws to increase the mandatory retirement age for non-employee directors, the CEO, and retired CEOs from 72 to 75. This change, effective December 10, 2013, allows the company to retain experienced directors for a longer period, potentially contributing to greater stability and continuity in governance.

Dr. Lynch's appointment to the Science and Technology Committee, coupled with his extensive background in cancer research and treatment, suggests a continued or strengthened focus on innovation and scientific advancement within Bristol-Myers Squibb. Investors may view this as a positive signal for the company's R&D pipeline, especially in oncology.

Dr. Lynch will receive compensation consistent with other non-employee directors. This includes an annual retainer of $90,000, an additional $15,000 for his service on the Science and Technology Committee, and an annual award of deferred share units valued at $160,000 at the grant date. This compensation structure is standard for board service and is not expected to represent a significant financial burden relative to the company's overall operations.